Suzhou Suncadia Biopharmaceuticals Co., Ltd. Drug Pipeline

Suzhou Suncadia Biopharmaceuticals Co., Ltd. maintains a substantial clinical development portfolio, with 76 trials registered since 2008, including 63 currently active. The pipeline spans all phases of clinical development, with 29 active Phase 1 trials, 32 in Phase 2, 20 in Phase 3, and 1 in Phase 4. The company’s research is heavily concentrated in Oncology, which accounts for 55 active trials, representing 87% of the active portfolio. Immunology programs account for the balance of clinical activity. Within Oncology, the leading indications are Solid Tumor (Advanced) with 18 active trials, Non-Small Cell Lung Cancer (NSCLC) with 8 active trials including 3 in Phase 3, Colorectal Cancer with 4 active trials including 2 in Phase 3, Cholangiocarcinoma with 4 active trials including 1 in Phase 3, and Hepatocellular Carcinoma with 3 active trials including 1 in Phase 3. The significant number of Phase 3 trials in Oncology suggests a potential for near-term clinical catalysts.